Objective
The efficacy and safety of yokukansan (YKS) for chronic renal failure (CRF) patients
receiving hemodialysis with behavioral and psychological symptoms of dementia (BPSD)
was evaluated.
Methods
Twelve CRF patients receiving hemodialysis with BPSD were recruited and 7.5 g of YKS
powder was added to ongoing therapy with antipsychotics. Neuropsychiatric Inventory
(NPI) criteria and Barthel Index before and after 4-week YKS treatment were compared.
Results
Analysis of the mean score for NPI revealed a significant improvement during the period
of YKS administration (25.3 ± 17.6 versus 8.36 ± 4.46; p = 0.0069). The mean score
for the Barthel Index showed no significant difference during the period of YKS administration.
Mean level of serum potassium was still within the normal range. No subjects had severe
adverse reactions necessitating discontinuation from the study.
Conclusion
Yokukansan significantly improved the symptoms of BPSD in CRF patients receiving hemodialysis
without critical side effects.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of Geriatric PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Psychiatric disorders among patients undergoing hemodialysis therapy.Nephron. 2002; 91: 344-347
- Cognitive impairment and 7-year mortality in dialysis patients.Am J Kidney Dis. 2010; 56: 693-703
- Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia.Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 881-885
- Pharmacokinetics of haloperidol in patients on hemodialysis.Nihon Shinkei Seishin Yakurigaku Zasshi. 1998; 18: 45-47
- Efficacy and pharmacokinetics of fluvoxamine maleate in patients with mild depression undergoing hemodialysis.Psychiatry Clin Neurosci. 2004; 58: 133-137
- Dangers of resonium A in the treatment of hyperkalemia in renal failure.Lancet. 1966; 1: 167
- Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies.J Clin Psychiatry. 2005; 66: 1612-1613
- Yi-gan san for the treatment of borderline personality disorder: an open-label study.Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 150-154
- Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32: 761-764
- Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice.Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34: 541-545
- Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats.Nutr Neurosci. 2008; 11: 41-46
- Anxiolytic effect of a herbal medicine, yokukansan, in aged rats: involvement of serotonergic and dopaminergic transmissions in the prefrontal cortex.J Ethnopharmacol. 2010; 127: 70-76
- Regulation of active sodium and potassium transport in the distal colon of the rat. Role of the aldosterone and glucocorticoid receptors.J Clin Invest. 1989; 84: 1924
- Binding of glycyrrhizin to human serum and human serum albumin.Chem Pharm Bull (Tokyo). 1989; 37: 226
- Human metabolism of orally ingested glycyrrhetinic acid and monoammonium glycyrrhizinate.Proc Soc Exp Biol Med. 1959; 102: 245
- Prevalence of hyperkalemia among hemodialysis patients in Egypt.Ren Fail. 2009; 31: 891-898
Article info
Publication history
Published online: March 13, 2013
Accepted:
June 6,
2011
Received:
February 24,
2011
Identification
Copyright
© 2013 Published by Elsevier Inc.
